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ABSTRACT 
RELATIONSHIP OF BE2 SURFACE ANTIGEN EXPRESSION TO T-CELL 
CLONALITY IN CUTANEOUS T-CELL LYMPHOMA AND SCLERODERMA 
Mittie Elizabeth Kelleher 
1990 
BE2 is a mouse monoclonal antibody raised against 
malignant CD4+ T-cells from a patient with cutaneous T-cell 
lymphoma (CTCL). Previous studies by Edelson et al suggested 
that BE2 expression serves as a marker of response to 
photopheresis in the treatment of CTCL, with a fall in the 
percentage of BE2+ lymphocytes correlating with clinical 
response. Subsequently, detection of BE2 on as much as 
30-40% of lymphocytes from some patients with scleroderma 
(PSS) was one factor which prompted a trial of photopheresis 
for the treatment of that disease. The role of BE2 in the 
response of patients to photopheresis is unknown, and the 
confirmation of its presence as a marker of the malignant 
clone in CTCL is unconfirmed. We have investigated the 
significance of BE2 antigen expression in identifying a 
clonal T-cell population in patients undergoing photopheresis 
for treatment of CTCL and PSS. Peripheral blood lymphocytes 
from 5 patients with leukemic phase CTCL were sorted by flow 
cytometry to separate BE2+ and BE2- cells, and analyzed by 
Southern blot analysis of the T-cell receptor J5 chain genes. 
Samples from all 5 patients showed monoclonal rearrangements 
of the T-cell receptor ft chain genes; however, there was no 
difference in the percentage of monoclonal cells in the BE2+ 
and BE2- populations. Further, DNA was analyzed from 6 
patients with PSS who had at least 20-30% BE2+ peripheral 

blood lymphocytes for evidence of a monoclonal T-cell 
popluation. All 6 patients had germline configurations of 
the ft chain genes. These studies confirm that BE2 antigen 
expression is not a marker restricted to a monoclonal 
population in these two groups of patients. In addition, 
alterations in expression of BE2, although perhaps a marker 
of clinical response to photopheresis in CTCL, probably do 
not correlate directly with cytotoxic activity against the 
malignant clone. 
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Cutaneous T-cell lymphoma (CTCL), a malignant neoplasm 
of CD4+ lymphocytes, begins as a cutaneous disease which then 
progresses to a leukemic phase with systemic involvement.1 
BE2 is a monoclonal antibody which was produced by immunizing 
mice with malignant CD4+ lymphocytes from a patient with 
CTCL.2 In a paper demonstrating the efficacy of 
extracorporeal photochemotherapy (photopheresis) in the 
treatment of CTCL, Edelson et al suggested that BE2 was 
useful as a laboratory marker of response to therapy with 
patients responding to photopheresis demonstrating marked 
decreases in the percentages of their lymphocytes expressing 
the BE2 surface antigen.2 Although the exact mechanism of 
photopheresis has yet to be elucidated, current theories 
favor the induction of an immune response directed against 
specific pathogenic T-cell clones.4 Investigative studies 
and clinical trials are currently under way to assess the 
usefulness of photopheresis in the treatment of a variety of 
diseases thought to be T-cell mediated including systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA), 
multiple sclerosis (MS), progressive systemic sclerosis 
(scleroderma or PSS), pemphigus vulgaris and organ transplant 
rejection.4 
The BE2 surface marker is not detectable on the surface 
of normal resting peripheral blood lymphocytes, but is 
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expressed by a population of B cell chronic lymphocytic 
leukemia lymphocytes, by the EBV transformed B cell line GM 
1056 and by the T-cell lines MOLT 3 and HUT 78 in addition to 
lymphocytes from patients with CTCL.2 Subsequent studies of 
the BE2 surface marker have suggested its importance as an 
activation marker and have demonstrated its presence on PHA, 
Con A and anti-CD3 stimulated normal T-cell lines.5 BE2 
expression by peripheral blood lymphocytes has been found in 
48% of patients infected with the acquired immune deficiency 
virus.6 Its presence on up to 36% of the peripheral blood 
cells of patients with progressive systemic sclerosis has 
recently been discovered.7 It has been proposed that 
scleroderma may be a T-cell mediated disease.8 Both CTCL and 
scleroderma have prominent cutaneous manifestations. 
With the cloning of the T-cell receptor, a powerful new 
method of identifying clonal populations of T-cells became 
available.9 Gene rearrangement studies using the 6 chain of 
the T-cell receptor as a probe have proven useful in 
definitively diagnosing and establishing the clonal nature of 
a variety of T-cell lymphoproliferative disorders.10-15 
Southern blot analysis using the ft chain of the T-cell 
receptor for the detection of gene rearrangements is capable 
of detecting clonal populations of T-cells which represent as 
few as 1% of peripheral blood components.16 In CTCL this 
method has proven to be superior to surface marker analysis 
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for diagnosis, staging and prognostic predictions.17'18 
Recent work aimed at characterizing the BE2 surface 
antigen marker has pointed to the value of identifying 
differences between BE2+ and BE2- populations of T-cells.5 
Our study was undertaken to test the hypothesis that the BE2 
surface marker is a marker of clonality. We hypothesized 
that BE2 expression might be restricted to the malignant 
T-cell clone present in CTCL. In order to test this theory, 
we subjected genomic DNA extracted from BE2+ and BE2- 
peripheral blood cells from patients with CTCL to Southern 
blot analysis using the B chain of the T-cell receptor to 
detect gene rearrangements indicative of clonal T-cell 
populations. In addition, we examined DNA extracted from 
peripheral blood cells from patients with PSS to further test 
the hypothesis that BE2 identifies a clonal population of 
T-cells by investigating whether there is a detectable clonal 
T-cell expansion present in the peripheral blood of patients 
with PSS. 
CUTANEOUS T-CELL LYMPHOMA (CTCL) 
CTCL is a malignant neoplasm of CD4+ lymphocytes which 
initially demonstrates preferential epidermal infiltration. 
Disease progression results in lymph node, peripheral blood 
and visceral involvement.19 It is generally accepted that 
the designation CTCL encompasses the disorders mycosis 
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fungoides and Sezary syndrome.20 Edelson has postulated 
that CTCL encompasses a wider variety of T-cell disorders 
with cutaneous manifestations including lymphoma cutis, 
histiocytic lymphoma and many adult T-cell leukemias.21 In 
his view, each of these entities falls within a continuous 
spectrum of a single type of malignancy.22 Each of these 
disorders is characterized by skin infiltration with 
neoplastic T-cells of the helper/inducer CD4+ phenotype.23-25 
Epidemiologic investigations intending to document the 
precise incidence of CTCL have been complicated by the 
fragmentation of the disorder into various subgroups. If 
Edelson's broad definition is used, CTCL now appears to have 
a cumulative incidence equal or exceeding that of Hodgkin's 
disease, making it the most common adult lymphoma.26 It 
occurs primarily in middle-aged white males though it may be 
seen in both men and women of all ages and races.27 
The exact etiology of CTCL remains unclear. 
Infectious, genetic and environmental causes have been 
proposed.28 Leukemia or lymphoma has been found in first 
degree relatives of 4% of patients with CTCL including the 
development of CTCL in a father and daughter.29 HTLV-1 has 
been isolated from the sera of patients with adult T-cell 
leukemia/lymphoma, a disease in which cutaneous infiltration 
may be seen, but is not a feature of most cases of CTCL.30 
Clinical Features. CTCL classically begins as flat 
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macules or patches (premycotic stage) which progress to 
papules or plaques which are slightly elevated (lichenoid 
stage) and then to large tumors or nodules. These stages may 
develop into an exfoliative erythroderma characterized by 
leukemic involvement. Palpable lymphadenopathy and 
hepatosplenomegaly reflect visceral involvement. 
The term mycosis fungoides, coined by Alibert in 1806, 
refers to mushroom like tumors protruding from a desquamating 
rash.31 This early epidermotropic phase is progressively 
replaced by aggressive nonepidermotropic lesions. The Sezary 
syndrome, first described in 1938, denotes the triad of 
erythroderma, leukemia composed of large mononuclear cells 
with convoluted nuclei, and enlarged lymph nodes.32 Plaques 
infiltrating the face may result in a "leonine facies," also 
seen in leprosy and leishmaniasis. Lesions, which commonly 
present on unexposed skin areas, vary in size and color and 
may be asymptomatic or intensely pruritic. Plaques may range 
in color from red to violet. Tumor formation may occur 
within a preexisting plaque or may arise in noncontiguous 
sites. Aggressive vertical spread into the reticular dermis 
and subcutis is referred to as "tumor d'emblee"33 and results 
in brilliantly colored lesions which occur preferentially on 
intertriginous areas and are predisposed to ulceration and 
secondary infection. In addition, these tumors are 
indicative of an aggressive malignant phenotype with a very 
poor prognosis. In patients with exfoliative erythroderma. 
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fissuring and scaling of the soles and palms may occur 
resulting in markedly diminished manual dexterity and painful 
ulceration. These patients often become cutaneous cripples 
who are handicapped physically as well as emotionally 
secondary to their disfigured appearance. Disseminated 
disease is characterized by lymphadenopathy and 
hepatosplenomegaly. Forty-seven percent of all patients and 
80-90% of those with erythrodermic stage disease have 
palpable lymphadenopathy.34 The bone marrow is uncommonly 
involved histologically; the absence of bone marrow 
involvement in the setting of leukemia is considered typical 
in CTCL.34 Extracutaneous disease is often not clinically 
apparent but frequently found at autopsy. Survival 
correlates directly with the existence of extracutaneous 
disease. Disseminated CTCL may involve virtually any organ 
system. Pulmonary, cardiac, gastrointestinal, renal, central 
and peripheral nervous system involvement have all been 
reported. Extracutaneous spread of the disease spares the 
bone marrow until extremely late in the course of CTCL when 
an "acute leukemic phase" may occur. 
Laboratory and Pathologic Findings. As stated 
above, CTCL is a malignant neoplasm of thymus-derived CD4+ 
lymphocytes. These cells have been shown to promote 
differentiation of normal B cells into immunoglobulin 
secreting plasma cells. This holds true for both leukemic 
phase cells and cells extracted from skin and lymph nodes.24 
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Immunophenotypic surface antigen studies have typically shown 
these cells to be CD3 + , CD4 + , CD8-, consistent with a 
"helper" phenotype.35 However, aberrant phenotypes may be 
found, especially in advanced cases of the disease.36 
Tissue distribution of the malignant cells is 
characteristic of the T-cell phenotype with lymph node and 
spleen involvement occupying the T-cell paracortex and 
periarteriolar sheath areas.37 Lymph nodes do not appear to 
serve as barriers to spread. Karyotypic studies of cells 
infiltrating distinct tissue sites have demonstrated 
identical chromosome banding patterns strongly suggesting 
that CTCL is the result of a monclonal proliferation of 
T-cells.38'39 No consistent karyotypic abnormality has been 
found in patients with CTCL though Shapiro et al found a 
slightly increased incidence of rearrangement of chromosome 
#10 which contains the gene for the interleukin-2 receptor.40 
The alpha, beta and gamma chains for the T-cell receptor are 
located on chromosomes 14q, 7q and 7p respectively.41'42 
Although no consistent chromosomal rearrangements involving 
these chromosomes have been reported, such rearrangements 
have been shown to occur sporadically in T-cell lymphomas. 
Perhaps the most definitive evidence demonstrating the clonal 
nature of CTCL has come from studies using the fi> chain of the 
T-cell receptor as a probe to detect gene rearrangements.17 
Patients with CTCL frequently have elevated serum Ig 
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levels, especially IgE and IgA, another finding consistent 
with a "helper" cell proliferation.43 Associated monclonal 
gammopathies and autoantibody production have been 
reported.44'45 Decreased levels of null cells have also been 
reported in CTCL.46 The role these abnormalities may play in 
the progression of the disease and the decreased resistance 
to viral infections found in some patients with CTCL is 
unknown. 
The observation that cutaneous involvement is 
pathognomonic of CTCL raises the possibility that malignant 
T-cells have an affinity for the skin. It has been 
hypothesized that CTCL may represent an exaggeration 'of the 
T-cell's physiologic homing mechanism to the skin.22 
Epidermal factors may be important in the epidermotropism 
demonstrated by CTCL. Monoclonal antibody studies have 
demonstrated increased epidermal interleukin-1 (IL-1) in the 
skin of patients with CTCL when compared with normal controls 
and patients with inflammatory dermatoses.47 It is under the 
influence o f IL-1 that T-cells produce IL - 2 and 
proliferate.43 This could provide a mechanism for local 
expansion of CTCL cells within the skin. 
Diagnosis. The diagnosis of CTCL can be difficult, 
especially in the early stages of the disease. Interestingly, 
many patients who eventually received the diagnosis of CTCL 
previously carried the diagnosis of a variety of dermatoses 
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including psoriasis, chronic contact dermatitis, eczema, 
pityriasis rubra pilaris or atopic dermatitis. This suggests 
either that these conditions may predispose a patient to the 
development of CTCL or more likely, that the diagnosis of 
CTCL is difficult in its early stages.27 The Mycosis 
Fungoides Cooperative Study Group found that 77% of patients 
previously carried the diagnosis of benign skin conditions 
with 32% of the diagnoses being "dermatitis not otherwise 
specified."49 
Historically, evidence from the history and physical 
examination was combined with light microscopic examination 
of hematoxylin and eosin stained sections of skin biopsies to 
detect typical morphologic patterns. Collections of 
mononuclear cells in the epidermis, termed "Pautrier 
microabscesses" were thought to be suggestive of patch stage 
CTCL. This term is a misnomer, since the word abscess 
implies a neutrophil infiltrate, and the infiltrating cells 
in these lesions are lymphocytes. However, an identical 
picture may be seen in chronic dermatitis, making this 
finding nonspecific. The cellular infiltrate of plaque stage 
CTCL is often composed of mononuclear cells with deeply 
indented nuclei; as the disease progresses, the cells become 
more atypical in appearance. Atypical lymphoid cells with 
distinctive hyperconvoluted or cerebriform nuclei accumulate 
first in T-cell areas of lymph nodes and then infiltrate the 
entire node, destroying its normal architecture as the 
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disease progresses.50 It is often impossible to distinguish 
dermatopathic lymphadenopathy from CTCL by light microscopic 
examination. Furthermore, patients with CTCL will often 
exhibit dermatopathic lymphadenopathy in addition to 
malignant changes, especially early on in their disease. The 
establishment of nodal involvement has diagnostic and 
therapeutic implications. Malignant lymph node involvement 
clearly portends a worse prognosis. It is rare for a patient 
to demonstrate visceral involvement in the absence of lymph 
node involvement.51,52 
Examination of peripheral blood cells may reveal the 
characteristic serpentine nuclei of Sezary cells; however, 
numerous investigators have proven that the presence of these 
cells is not restricted to CTCL. They may also be found in 
psoriasis, lichen planus and in benign cutaneous 
conditions.53 In addition, the existence of nonneoplastic 
circulating Sezary-like cells, thought to represent reactive 
lymphocytes, has been documented in patients with CTCL.54 
The ultrastructural features of these distinctive cells by 
electron microscopy have also proven not to be specific for 
CTCL.55 
DNA cytophotometry which quantitates abnormalities of 
nuclear DNA content, and cytogenetic (karyotypic analysis) 
studies have also been used to diagnose CTCL. While 
karyotypic analysis is more sensitive than DNA 
cytophotometry, both methods are technically difficult to 
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perform and have variable specificity. Immunophenotypic 
analysis has a limited but useful role in distinguishing CTCL 
from other lymphoid disorders.56 The detection of clonal 
rearrangements of the T-cell receptor genes by Southern blot 
analysis, which was instrumental in determining the clonal 
nature of this disorder, may be the most definitive 
diagnostic test for patients with CTCL. The method is 
substantially more sensitive than histologic examination of 
lymph node specimens for the detection of occult disease.17 
It also establishes an effective test useful for assessing 
the peripheral blood of these patients.18 The utility of 
this technique has not been extended to the diagnosis of 
plaque or early stage disease. Ralfkiaer et al found no 
evidence of a monoclonal population in skin biopsies from 12 
patients, 8 of whom had histologically nondiagnostic, but 
clinically suspicious, lesions and 4 of whom had stage II 
mycosis fungoides.57 
A combination of the aforementioned diagnostic 
techniques currently provides the most complete assessment of 
a patient's disease involvement. Patients with CTCL are 
staged according to a modified TNM system.58 Peripheral 
blood involvement is not incorporated into the TNM 
classification; it is thought to be a separate prognostic 
factor which may correlate with total body tumor burden.59 
Mycosis fungoides, unlike Hodgkin's lymphoma, does not 
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progress in an orderly fashion from one chain of lymph nodes 
to the next. Prospective studies strongly indicate that CTCL 
spreads hematogenously rather than by extension via the 
lymphatics. Once the malignant cells invade beyond the 
confines of the skin, the lymph nodes do not provide a 
barrier to further spread. Thus, widespread dissemination is 
to be expected in patients with evidence of lymph node 
involvement.49 
Treatment . The choice of appropriate treatment 
depends on accurate staging. Early patch or plaque stage 
lesions may be successfully treated with topical or 
intralesional corticosteroids.60 Topical nitrogen mustard or 
mechlorethamine may also effectively control limited 
cutaneous disease as will carmustine or 
bischloroethyl-nitrosurea (BCNU) . 61'62 Patients with purely 
cutaneous involvement may show dramatic improvement following 
treatment with 8-methoxypsoralen plus ultraviolet A light 
(PUVA)63'64, a therapy first proven to be effective in the 
treatment of psoriasis.65 
Eight-methoxypsoralen (8-MOP) is absorbed orally. Peak 
plasma levels are reached within two to three hours. In the 
presence of UVA light 8-MOP forms covalent DNA photoadducts 
with pyrimidine bases.66 Only 60% of UVA light penetrates to 
the dermis and less than 1% to the subcutis. Thus, this 
therapy does not affect deep tumor infiltrates or sites of 
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visceral involvement.63 PUVA must be given 2-3 times per 
week until intial skin clearing occurs at which time 
maintenance therapy is required. Electron-beam treatment may 
also be useful in CTCL confined to the skin.67 Leukapheresis 
may provide palliative therapy for patients with 
erythrodermic stage CTCL.68 
Each of the above treatments is effective for patch or 
plaque stage CTCL without lymph node, visceral or leukemic 
involvement. Systemic chemotherapy is merely palliative for 
advanced disease.69 However, occult systemic involvement, 
common in advanced disease, may exist at the time of 
presentation.70 A recently completed randomized trial 
compared combination electron-beam radiation and chemotherapy 
to topical treatment. The results showed no advantage of 
aggressive initial treatment in comparison to conservative 
treatment.71 
Prognosis. CTCL carries a prognosis which clearly 
depends on disease stage at the time of diagnosis, since 
effective therapies exist for disease limited to the skin. 
In a retrospective study, Epstein et al analyzed 144 patients 
at the National Cancer Institute, all of whom had skin biopsy 
findings consistent with mycosis fungoides.72 Mean survival 
after the appearance of skin lesions was 8.8 years, with the 
mean survival from the time of histologic diagnosis being 
less than 5 years. The presence of palpable lymphadenopathy 
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or cutaneous tumors reduced mean survival to 2.5 years, and 
patients with hepatomegaly and/or splenomegaly had a mean 
survival of only 3 months. 
Lamberg et al identified several other prognostic 
factors. Plaque, papule or patch stage involvement covering 
more than 10% of the total body surface area correlates with 
a poorer prognosis, as does generalized erythroderma and/or 
cutaneous tumors.49 Individuals with erythrodermic CTCL have 
a median survival less than 30 months. Patients with CTCL 
usually die from infectious complications resulting from 
their underlying disease, from therapy, or from complications 
of involvement of vital organs.72 
EXTRACORPOREAL PHOTOCHEMOTHERAPY (PHOTOPHERESIS) 
Dramatic progress in the treatment of CTCL occurred 
when Edelson et al developed a new treatment for systemically 
disseminated disease. As previously mentioned, PUVA, in 
which a patient's skin is exposed to UVA light following the 
oral administration of methoxsalen has proven efficacy in 
plaque stage CTCL.63'64 This knowledge, combined with the 
fact that leukapheresis provided effective treatment for some 
patients prompted Edelson to test the hypothesis that 
exposing leukocytes to the effects of PUVA might be 
efficacious for leukemic phase disease. Since neither 
platelets nor red blood cells contain nuclei, they would not 
be affected by the treatment and could be returned to the 
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patient. Returning these cells to the patient would prevent 
the occurence of anemia and thrombocytopenia, limiting side 
effects of leukapheresis. His hypothesis evolved into an 
effective treatment known as photopheresis.73 
In the initial multicenter trial of photopheresis, 41 
patients were treated. Thirty-three had generalized 
erythroderma, and 8 had localized plaques. Each patient had 
circulating atypical mononuclear cells and a diagnostic skin 
biopsy. After ingesting .6 mg/kg body weight of methoxsalen, 
240 mis of leukocyte enriched blood containing 30-50% of the 
patient's circulating lymphocytes were passed as a 1 mm film 
through a sterile cassette exposed to UVA light at 1-2 joules 
per square cm prior to being returned to the patient. 
T-cell subsets using monoclonal antibodies were 
determined for each patient. Additionally, reactivity with 
BE2 was tested. Lymphocytes from 4 patients in the study 
were exposed to 8-MOP and UVA light but not returned to the 
patient so that the viability of these cells following 
treatment could be determined. Seventy-two hours after 
treatment only 12 +/- 5% of these lymphocytes were viable as 
determined by trypan blue exclusion. The author further 
noted that more than 25% of the lymphocytes from these 
patients were BE2+. This observation suggested that if 
reactivity with the BE2 antibody is specific for the 
malignant clonal population, then the levels of 8-MOP and UVA 




Of the initial 41 patients, 37 completed the trial. 
All had failed prior therapy, which included systemic 
chemotherapy, e1ectron-beam radiotherapy, topical 
mechlorethamine, or PUVA directed at the skin. Side effects 
typically seen with systemic chemotherapy such as alopecia, 
bone marrow suppression and GI erosions did not occur. 
Notably, a post-reinfusion febrile spike occurred in four 
patients, all of whom ultimately responded to treatment. 
Twenty-seven of these patients responded to treatment. Of 
the 28 patients who had failed systemic chemotherapy, 20 
responded to photopheresis. Twenty-four of 29 patients with 
exfoliative erythroderma responded while 3 of 8 with 
localized plaques and tumors showed a positive response. 
Response was defined as a 25% reduction in the baseline 
overall skin lesion score maintained for at least 4 
consecutive weeks. Nine patients showed more than 75% 
response, 13 showed 50-75% response and 5 a 25-49% response. 
Eleven of the patients were shown to carry clonal 
populations of T-cells as determined by T-cell gene 
rearrangement studies or karyotypic analysis. No consistent 
changes in total leukocyte counts, lymphocyte percentages or 
the number of circulating Sezary cells were found. However, 
when the 11 patients with clonal T-cell populations were 
analyzed individually, the following observations were noted. 
Six of these patients initially had >90% CD4+ cells with 3 
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patients demonstrating higher percentages of CD4+ cells than 
CD3+ cells, possibly indicating abnormally deficient CD3 
expression by these malignant cells. During the course of 
treatment, the CD4/CD3 ratio progressively decreased in these 
patients. 
Of particular interest to us, was the fact that in the 
5 subjects who had initially elevated BE2+ levels all 
exhibited a significant decrement in BE2 upon achievement of 
a clinical response. The author suggested that the BE2 
marker distinguishes the malignant T-cells of some patients 
from their normal helper/inducer T-cells and permitted a 
laboratory correlation of the response to therapy. In 
addition, those patients who experienced a substantial 
decrease in the percentages of their cells expressing the BE2 
marker after treatment, also exhibited a continued decline of 
the BE2 population. Levels remained very low for several 
months. In 2 patients the decrement persisted for more than 
2 years, an observation which correlated with quiescent 
disease activity. 
The exact mechanism of photopheresis remains elusive. 
The photodestruction of large numbers of T-cells belonging to 
an expanded clone may, upon introduction to an intact 
reticuloendothelial system, provoke a specific immunologic 
reaction directed against the expanded clone. Experiments in 
animal systems have shown that the injection of specific 
autoreactive clones of T-cells can induce a variety of 
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autoimmune syndromes including encephalomyelitis, arthritis 
and thyroiditis. Experimental autoimmune encephalomyelitis 
(EAE), adjuvant arthritis (AA) and experimental autoimmune 
thyroiditis (EAT) are all T-cell mediated organ specific 
diseases.74 Investigators have also demonstrated, however, 
that the infusion of lethally damaged specific autoreactive 
T-cell clones leads to resistance to autoimmune disease upon 
subsequent infusion of viable pathogenic T-cell clones.75'76 
Resistance to subsequent induction of autoimmune disease has 
been attributed to a specific clonotypic immune activation, 
perhaps via the induction of specific suppressor-inducer T 
lymphocytes. Cohen refers to this phenomenon as "'T-cell 
vaccination." Vaccination is achieved by treating the cells 
with hydrostatic pressure or with chemical crosslinkers such 
as formaldehyde or glutaraldehyde that crosslink cell 
membrane components.77 These methods are effective in 
preventing disease though they do not affect already 
established disease. 
Other groups have recently shown that exposure of cells 
to 8-MOP/UVA may produce a "vaccination" process identical to 
other methods used by Cohen and his group. This is 
particularly significant because hydrostatic pressure and 
formaldehyde are not treatments which could easily be adopted 
for use in human subjects. However, numerous clinical trials 




Khavari et al have shown that photoinactivation of 
cells with 8-MOP/UVA effectively protects against the 
development of EAE.78 Perez has similarly demonstrated that 
these cells, termed "photoinactivated effector lymphocytes" 
can induce tolerance for skin allotransplantation in murine 
models.79 This method has also proved to be effective in 
preventing a murine SLE-like syndrome related to an 
unregulated proliferation of benign aberrant inducer 
T-cells .80,81 Berger has recently shown in animal models 
that photoinactivated spleen cells show, upon reinjection, 
increased sequestration by the bone marrow, spleen, and 
kidney - sites where an immune response may be induced. 
Furthermore, photopheresis added to conventional 
immunosuppressive regimens has prolonged graft survival, 
suppressed the mixed leukocyte culture response to the donor, 
and suppressed antidonor antibody formation in a primate 
cardiac xenograft model.82 
While 8-MOP/UVA is thought to exert its effect at the 
DNA level via pyrimidine crosslinking,66 the identification 
of high affinity binding sites on the cell surface raises the 
possibility of a mechanism of psoralen toxicity not involving 
DNA intercalation.82 Photopheresis is not specifically 
targetted at malignant or aberrant T-cell clones, but 
expanded T-cell populations are probably damaged more 
extensively than other cells. This might result in selective 
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destruction of the malignant clone by intact cells of the 
immune system not exposed to the damaging effects of 
8-MOP/UVA.73 Photopheresis has received FDA approval for the 
treatment of advanced CTCL.84 In accordance with this 
principle, extensive clinical experience involving 
photopheresis for the treatment of CTCL has shown that 
immunocompetent patients identified by PHA stimulation assays 
responded best.85 Patients who are not immunocompetent may 
respond to frequent treatments, but this response is thought 
to result from simple physical destruction of malignant cells 
and is not long-lived.86 
The possibility that exposing nonfractionated 
peripheral blood lymphocytes to 8-MOP/UVA treatment can 
result in a specific clonotypic response has particularly 
attractive therapeutic implications. Photopheresis does not 
require isolation of specific aberrant clones, a feat which 
has not yet been possible. In addition, as already stated, 
the treatment has minimal systemic toxicity. Currently, 
clinical trials are underway to investigate the efficacy of 
photopheresis in a variety of diseases including autoimmune 
disorders such as SLE, RA, PSS and pemphigus vulgaris. A 
clinical trial involving patients with chronic lymphocytic 
lymphoma (CLL) is also in progress, and there perhaps lies a 
role for photopheresis in the area of organ 
transplantation.87'88 Preliminary results in patients with 
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pemphigus vulgaris have been striking.89 Clinical trials in 
CLL and discordant xenograft protocols in which preformed 
antibodies exist, should help elucidate the effect of 
photopheresis on B cells. 
BE 2 
BE2 is a murine monoclonal antibody produced by 
immunizing mice with leukemic helper T-cells from a patient 
with CTCL.2 When purified, the BE2 antibody precipitated a 
single 78,000 D molecule from CTCL cells. Reactivity was 
determined by indirect immunofluorescence and 
immunoperoxidase staining. By these methods BE2 reacted 
strongly with CTCL cells. Ten percent reactivity, which was 
two standard deviations above normal background, was chosen 
as the cutoff for significant reactivity. 
Cells from 5 of 8 patients with B cell CLL reacted with 
BE2 . The antibody also reacted with lymphocytes from one 
patient with leukemic CTCL and with lymphocytes from a lymph 
node of a patient with non-leukemic CTCL. It reacted with 
lymphocytic infiltrates in skin biopsy and lymph node 
specimens in patients with advanced CTCL. Normal lymph 
nodes, uninvolved epidermis and thymus sections did not react 
with BE2 on the basis of immunoperoxidase staining. Normal 
tissues screened included thyroid, skin, breast, thymus, 
colon, liver, kidney, lung, heart, brain and lymph node. BE2 
showed strong affinity for EBV transformed B cell lines by 
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radioimmunoassay. The long term cell lines MOLT 3 and HUT 78 
also reacted with BE2. The antibody did not react with four 
melanoma cells lines, two breast cancer lines, a colon cancer 
line and promyelocytic, myelocytic, erythroid, or null cell 
lines . 
Twenty-one patients with clinical CTCL, without 
apparent lymph node involvement were tested for peripheral 
blood reactivity to BE2 . Five patients (Group I) were 
subsequently found to have disseminated disease by lymph node 
biopsy and karyotypic analysis. Four of these five patients 
showed >10% reactivity with BE2. Every patient with proven 
extracutaneous disease had peripheral blood cells reactive 
with BE2 . Eight patients (Group II) had widespread 
erythroderma. Five of these patients reacted with BE2. Of 
note, 3 patients with advanced disease did not react with the 
BE2 antibody. Group III consisted of another 8 patients with 
evidence of disseminated disease. Four of these patients 
reacted with BE2; less than 10% of the circulating 
mononuclear cells from the other 4 patients reacted with BE2. 
Thus, 62% or 13 of 21 patients demonstrated reactivity to 
BE2 . Ten of these patients had no clinical evidence of 
extracutaneous disease. 
Overall, 8 patients did not demonstrate reactivity with 
BE2, with 3 of these patients having evidence of disseminated 
disease. This latter observation led the authors to 
hypothesize that patients with end stage aggressive disease 
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may lose the BE2 antigen. A more likely explanation would be 
that BE2 is simply not expressed on all CTCL cells. The 
authors postulated that reactivity with the antibody BE 2 
signified the presence of extracutaneous disease. However, 
only 4 of these patients had evidence of extracutaneous 
disease on the basis of lymph node biopsy or karyotypic 
analysis. Importantly, 61% of the reactive patients had no 
clinical evidence of disseminated disease and were suspected 
of having extracutaneous disease solely on the basis of 
reactivity with this antibody. 
PHA stimulated mononuclear cells from normal controls 
and purified normal B cells also did not demonstrate 
reactivity. Patients with widespread psoriasis and normal 
controls were shown to be nonreactive with BE2. 
In summary, Berger et al concluded that BE2 is present 
on several transformed T and B-cell lines in addition to 
lymphocytes from patients with CTCL. They further concluded 
that the absence of BE2 expression by normal lymphocytes and 
normal tissue suggested that its expression is restricted to 
neoplastic cells of lymphoid origin; they further postulated 
that BE2 expression might therefore be useful in identifying 
small numbers of neoplastic cells. Finally, they propose 
that further studies aimed at isolating and characterizing 
the BE2 antigen should reveal its functional role. They also 
suggest that if BE2 is a specific tumor-associated antigen, 
further studies might clear new pathways for therapy of CTCL. 
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Berger's group extended this work by studying the in 
situ cutaneous infiltrate of 5 patients with digitate 
dermatosis, 12 with pityriasis lichenoides chronica, 3 
patients with lymphomatoid papulosis and 3 with cutaneous B 
cell lymphoma. In the same study 19 patients with CTCL were 
reactive with the BE2 marker. Among the other dermatoses 
investigated only one patient with lymphomatoid papulosis and 
one patient with cutaneous B cell lymphoma reacted with BE2 . 
From this study the authors concluded that the BE2 antigen 
allows unambiguous tissue diagnosis of CTCL.90 Another group 
reported that patients with actinic retinoid failed to react 
with BE2.91 
In contradiction to Berger's results, Ralfkiaer et al 
concluded that BE2 is neither T-cell nor tumor specific.92 
Ralfkiaer et al examined a comprehensive range of nodal and 
cutaneous biopsies immunohistological ly using single and 
double immunofluorescent staining methods. BE2 demonstrated 
an extremely broad range of reactivity. It consistently 
labelled normal endothelial cells, mantle and marginal zone B 
cells, and T-cells in the lymph node paracortex and thymic 
medulla. It also labelled Langerhans cells and dermal 
macrophages. Seventeen of 28 cases of malignant T-cell 
lymphoma studied showed reactivity with BE2. T-cells from 4 
of 19 benign dermatoses also reacted with BE2. Clearly, the 
antibody reacted in a nonspecific fashion. 
The authors employed a multistage staining method. For 
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double staining, sections were incubated with a mixture of 
anti-BE2 antibody, an IgGI antibody, and anti-LeuI, an IgG2a 
antibody, followed by staining with fluorescein and rhodamine 
conjugated rabbit antibodies against mouse IgGI or IgG2a 
immunoglobulin subclasses. Omission of the primary 
monoclonal antibody, substitution of an IgG2a reagent for the 
IgGI antibody and similar substitution of an IgGI reagent for 
an IgG2a reagent were used as negative controls. 
Substitution of secondary antibody should not be used as a 
negative control. Ideally, negative controls should be 
stained under identical conditions with identical reagents on 
a known negative population of cells. The lack of 
appropriate controls in this study renders their conclusions 
ambiguous. 
Berger et al later demonstrated that 48% of patients 
with the acquired immunodeficiency syndrome (AIDS) had 
peripheral blood populations which reacted with BE2 . 6 
Interestingly, the HTLV-I virus, a member of the retrovirus 
family which includes the AIDS virus, has been isolated from 
the CTCL patient whose lymphocytes were used to immunize mice 
to produce the BE2 antibody.30 
It would be interesting to know how many of the AIDS 
patients in the study had skin involvement with Kaposi's 
sarcoma or other cutaneous disorders. The authors did state 
that AIDS patients with and without Kaposi's sarcoma were 
among the BE2+ population. The authors propose that BE2 may 
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be a normal cellular product whose expression can be induced 
by retroviral infection. Humoral titers of HTLV-I were not 
elevated in the BE2+ AIDS population. The previous 
demonstration of BE2 expression by an EBV transformed B cell 
line makes the restriction of BE2+ expression to T-cells in 
AIDS patients of interest. Finally, the authors propose that 
the BE2 antigen may be restricted to a small subset of normal 
T-cells which have been expanded in response to a chronic 
antigenic challenge. 
Recently, induction of BE2 expression by normal T-cells 
and by BE2- CTCL cells has been reported.5 Induction 
followed stimulation of the cells with PHA, Con A, allogeneic 
leukocytes, and anti-CD3 monoclonal antibody. It was also 
noted that BE2 antibody inhibits PHA induced thymidine 
incorporation and IL-2 expression, leading investigators to 
conclude that the antigen has a role in T-cell activation. 
Thus, in contradiction to earlier suggestions, the authors 
assert that the BE2 antigen may be a functional membrane 
protein and that its expression may be a normal physiologic 
process which is altered in CTCL. 
BE2 is proposed to be a late activation antigen which 
directly contributes to cell proliferation. According to 
this hypothesis, CTCL patients may be divided into those 
whose cells constitutively express BE2 and those in whose 
cells expression can be induced. The authors also imply that 
photopheresis is more effective in CTCL patients with 
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circulating BE2+ cells. The presence of BE2 antigen 
expression may reflect activated circulating malignant cells; 
these may be necessary for the induction of a T-cell specific 
clonotypic response. 
In summary, BE2 is a murine monoclonal antibody raised 
against malignant CD4+ cells from a patient with CTCL. It 
reacts with approximately 75% of the peripheral blood cells 
of patients with CTCL. It does not react with peripheral 
blood cells from normal controls, but is detectible in 48% of 
patients infected with AIDS. In addition, it reacts with B 
cell CLL lymphocytes, an EBV transformed B cell line and two 
T-cell lines. Induction of BE2 expression on normal T-cells 
and PHA, Con A and anti-CD3 stimulated BE2- cells has 
suggested its importance as an activation antigen. 
PROGRESSIVE SYSTEMIC SCLEROSIS (PSS OR SCLERODERMA) 
The recent revelation that patients with PSS 
constitutively express BE27 provided us with an ideal 
population of patients in whom to test the hypothesis that 
BE2 expression is restricted to either a malignant T-cell 
clone or an expanded and perhaps autoreactive clone. In 
addition, the documentation of a detectable T-cell clone in 
patients with PSS could have important therapeutic 
implications with respect to the usefulness of photopheresis 
in PSS. 
Progressive systemic sclerosis is a generalized 
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disorder of unknown etiology characterized by excessive 
connective tissue accumulation. The classic finding in the 
disease is induration or thickening of the skin 
(scleroderma). The disease is also characterized by 
systemic fibrosis of the heart, lungs, kidneys, 
gastrointestinal tract, muscles and synovium. Vascular and 
microvascular abnormalities are prominent features of the 
disease. The characteristics of PSS, which have been 
reviewed thoroughly,93 will be summarized briefly here. 
Epidemiology. Systemic scleroderma is usually 
diagnosed in the fifth or sixth decade. Its distribution is 
global with blacks being affected more often than whites and 
females being affected approximately three times as often as 
males. Clear occupational and environmental exposure risks 
have been identified with silica dust being of particular 
note. Numerous studies have suggested a heritable component 
to the disease. More than 25% of blood relatives have +ANA 
titers compared to 5-8% of controls; however, monozygotic 
twin studies do not point toward a clear genetic 
predisposition, and family studies have not established a 
predominant HLA haplotype. Chromosomal instability, observed 
in spontaneous mitoses from bone marrow, has been reported. 
An increased incidence of random chromosomal breakage has 
also been described in patients with PSS and their 
asymptomatic relatives. 
Clinical Features. Patients with limited cutaneous 
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disease often present with an initial complaint of Raynaud's 
phenomenon while patients who go on to develop diffuse 
scleroderma often present with skin tightening or arthritis. 
In rare patients, internal manifestations are the first sign, 
or internal disease may exist in the absence of cutaneous 
involvement. 
Cutaneous involvement usually progresses from an 
initial edematous phase to an indurative phase which may 
eventually soften or enter an atrophic phase. 
Histologically, accumulations of mononuclear cells, mostly T 
lymphocytes, are found in the lower dermis and subcutis. 
Mast cells are often found in early disease. There is also a 
marked increase in the number of compact collagen fibers in 
the reticular dermis, loss of rete pegs, and thickening of 
the epidermis. Areas of hyper- and hypopigmentation occur 
over the thickened skin creating a "salt and pepper" 
appearance. Intra- and subcutaneous calcifications may form, 
often on digital pads and periarticular tissues, and along 
extensor surfaces and bursal areas . Ulcerations and 
secondary bacterial infections may complicate the clinical 
picture. 
Ninety-five percent of patients with PSS have Raynaud's 
phenomenon. Narrowing and obstruction of the digital 
arteries can be demonstrated. Patients frequently complain 
of polyarthralgias and joint stiffness. A predominant 
mononuclear infiltrate may be found in involved large joints 
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and inflammatory cells are also found in the synovium. 
Tendinous and periarticular fibrosis results in joint 
contractures. The terminal phalanges may demonstrate erosive 
arthropathy. Muscle atrophy may result from disuse or may be 
secondary to myopathy from inflammation or indolent 
connective tissue fibrosis. Muscle biopsies show focal 
collections of plasma cells and lymphocytes mostly in 
perivascular areas. 
Gastrointestinal involvement is a significant cause of 
morbidity. Microstomia and microchelia are often present, 
and thickening of the periodontal membrane and loss of the 
lamina may result in loosening of the teeth and gingivitis. 
Ninety percent of patients develop esophageal 
dysfunction, the most common internal manifestation. 
Symptoms of dysphagia often precede cutaneous disease. 
Incompetence of the lower esophageal spincter results in 
gastroesophageal reflux and esophagitis. Smooth muscle 
atrophy and fibrosis and lymphocyte and plasma cell 
infiltration of the lamina propria are seen histologically. 
These patients have a predisposition for the development of 
Barrett's esophagus. 
Gastric involvement may result in delayed emptying. 
Abdominal pain, nausea, vomiting, weight loss and bloating 
are symptoms which reflect small intestine involvement. 
Malabsorption and vitamin B12 deficiency result from 
bacterial overgrowth. Histologic changes are identical to 
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those seen in the esophagus. Such changes may also exist in 
the colon, resulting in diarrhea, constipation or 
obstipation. Wide neck diverticula, usually on the 
antimesenteric border of the transverse and descending colon, 
are unique to scleroderma. 
Primary biliary cirrhosis has been seen in patients 
with scleroderma, particularly those who also have Sjogren's 
syndrome. These patients have antimitochondrial antibodies, 
usually directed against a 72,000 D M2 autoantigen. 
The respiratory system is affected in over 70% of 
patients with scleroderma. Exertional dyspnea is the most 
commmon symptom, often accompanied by a dry, nonproductive 
cough. Bibasilar crackles are often heard on physical exam, 
and chest radiographs often demonstrate diffuse linear and 
nodular fibrosis. PFT's are also diffusely abnormal with a 
reduced diffusing capacity being characteristic. Patients 
generally experience a progressive deterioration in pulmonary 
function. Idiopathic pulmonary fibrosis with alveolar and 
interstitial fibrosis is the histopathological finding. Loss 
of septa may lead to honey-combing. In early disease 
alveolitis with infiltration by lymphocytes, macrophages, 
neutrophils and eosinophils is seen. Many investigators feel 
that lung fibroblasts are stimulated by mononuclear cell 
products. 
Cardiovascular manifestations of scleroderma consist 
primarily of pericarditis, left ventricular or biventricular 
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congestive failure or arrrythmias. Diffuse atrophy and 
myocardial fibrosis are the histopathologic changes seen and 
are thought to occur secondary to vasomotor and 
mirocirculatory dysfunction (myocardial Raynaud's 
phenomenon) . Coronary artery disease does not occur with 
greater frequency in patients with scleroderma. 
Renal involvement is a prominent internal manifestation 
in scleroderma and a major cause of mortality in these 
patients. Clinical features range from asymptomatic 
proteinuria to scleroderma renal crisis (malignant arterial 
hypertension, pulmonary edema and renal failure) . Renal 
blood flow abnormalities include decreased renal plasma flow 
and a reduction in renal cortical blood flow. Constriction 
of the interlobular arteries and afferent arterioles is seen. 
Twenty-five percent of patients develop hypertension. 
Angiotensin converting enzyme inhibitors have markedly 
decreased hypertension associated mortality. Immunoglobulin, 
fibrinogen and complement deposition, with IgM being the 
major immunoglobulin present, are seen. Electron microscopic 
studies have not revealed the presence of immune complexes. 
Anemia may occur late in the course of disease, but 
hematologic abnormalities are uncommon. Primary CNS 
involvement is unusual; trigeminal neuralgia is a rare 
presenting complaint and is associated with anti-RNP 
antibodies. Cerebral arteritis has been reported. In males, 
impotence may result from reduced penile blood flow. 
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Keratoconjunctivitis sicca, often seen in association with 
Sjogren's syndrome, is the primary ocular manifestation. 
Hypothyroidism occurs in up to 25% of patients and is 
associated with antithyroid antibodies. Sjogren's syndrome 
with lymphocytic infiltration of the minor salivary glands is 
frequently seen in patients with scleroderma. 
Prognosis. Systemic sclerosis runs a variable 
course. The presence of cutaneous thickening prior to the 
onset of Raynaud’s phenomenon, rapid disease progression with 
proximal extremity involvement, serum anti Scl-70 antibody 
and palpable tendon friction rubs all herald a poor 
prognosis. Late in the disease, skin may spontaneously 
soften as other manifestations also subside. Most patients, 
however, progress to visceral involvement. Male gender, 
advanced age, and renal, cardiac or pulmonary involvement are 
all poor prognostic factors. 
Pathogenesis. Although the pathogenic mechanism in 
PSS remains unclear, clear vascular and immunologic 
abnormalities are associated with the overproduction of 
connective tissue proteins and collagen. Excess production 
of collagen is the hallmark of scleroderma. Skin biopsy 
explants from patients with scleroderma produce excess 
amounts of collagen and glycosaminoglycans, particularly 
hyaluronic acid and collagen. Increased levels of proline 
hydroxylase and lysosyme hydroxylase, enzymes involved in 
collagen metabolism occur. Normal fibroblasts incubated with 
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serum from patients with PSS demonstrate increased 
proliferation. It appears that fibroblasts producing high 
levels of collagen, perhaps a subpopulation of cells, 
selectively proliferate. 
Clinical and histopathological evidence of vascular 
abnormalities in scleroderma is abundant. It has been 
proposed that the vascular endothelium is the major target 
organ. Concentric intimal hypertrophy occurs and the 
adventitia becomes surrounded by fibrotic tissue. The 
microvasculature shows endothelial swelling, duplication of 
the capillary basement membrane, and loss of normal 
capillaries. Elevation of a number of endothelial and 
platelet factors has been demonstrated, including von 
Willebrand factor, VUI-von Willebrand antigen, circulating 
platelet aggregates and beta-thromboglobulin. Increased 
thromboxane and prostacyclin synthesis has been reported. 
Ultrastructural examination of the endothelium of patients 
with PSS reveals platelets adherent to the basement membrane 
in damaged endothelial cell gaps. Platelet-derived growth 
factor (PDGF), released by activated platelets, is 
chemotactic and mitogenic for fibroblasts, and may have a 
role in the pathogenesis of scleroderma by inducing intimal 
proliferation. Connective tissue activating peptide-II (low 
affinity platelet factor 4), shown to be mitogenic for human 
fibroblasts, may also be involved. Abnormalities of 




Multiple immunologic abnormalities are found in 
patients with scleroderma, suggesting a central role for the 
immune system in the pathogenesis of the disease. The 
coexistence of scleroderma with other collagen vascular 
disorders, such as rheumatoid arthritis, Sjogren's syndrome, 
and autoimmune thyroiditis, provides clinical evidence of its 
association with classic immune mediated conditions. 
Additional indirect evidence also comes from the 
scleroderma-like skin changes which are seen in 
graft-versus-host disease (GVHD), a syndrome which is clearly 
immunologically mediated. 
Abnormalities of both humoral and cellular immunity 
have been identified in scleroderma. Hypergammaglobulinema, 
typically elevated IgG levels, is found in greater than a 
third of patients. The existence of monoclonal gammopathies 
has been reported. Circulating immune complexes are 
sometimes detected in small quantities, primarily in patients 
wih detectable autoantibodies. Up to one third of patients 
with PSS are positive for Rheumatoid factor. Uncommonly, LE 
cells can be demonstrated, and rare patients have +VDRL 
titers. 
More than 90% of patients have circulating antinuclear 
antibodies although titers are lower than those usually found 
in SLE. Nuclear staining patterns observed include fine 
diffuse speckles, larger discrete speckles, centromere and 
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nucleolar staining. The fine, diffuse speckled pattern 
correlates with antibodies to the Scl-70 antigen, a 
nonhistone nuclear protein now known to be the nuclear enzyme 
DNA topoisomerase I. Although only about one-fifth of 
patients with scleroderma are positive for the Scl-70 
antibody, the marker is highly specific. Anticentromere 
antibodies occur most commonly in patients with limited 
scleroderma with 50-96% of patients with the CREST variant 
possessing these antibodies. 
Antinucleolar antibodies are common in patients with 
Sjogren's syndrome in addition to PSS. A variety of other 
antibodies including anticentriole and anti-ssRNA antibodies 
have been reported. Antilymphocyte antibodies are frequently 
present. Antibody to type I and type IV (basement membrane) 
collagen have been correlated with a reduced pulmonary 
diffusion capacity. 
Numerous abnormalities of cellular immunity have been 
reported in patients with scleroderma. Cellular infiltrates, 
primarily T lymphocytes, but also collections of plasma 
cells, can be detected in the skin, synovium, lung, GI tract 
and other locations early in the disease course. Levels of 
T-cells in the peripheral blood are often decreased. There 
is no typical change in the number of B cells. Hughes et al 
hypothesized that this reduction in peripheral blood T-cells 
is secondary to tissue sequestration. As stated above, skin 
infiltrates consist primarily of T-cells. Surface marker 
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studies have revealed an elevated CD4+/CD8+ ratio secondary 
to a decrease in circulating CD8+ cells in approximately one 
third of patients. Others have attributed the altered ratio 
to increased helper T-cell populations. 
Recently, the role of lymphokines and monokines in the 
pathogenesis of connective tissue disease has been 
investigated. Lymphocytes from patients with PSS, when 
stimulated by normal human collagen or animal collagen 
extracts, produce leukocyte chemotactic factor and leukocyte 
migration inhibition factor. This raises the possibility 
that persistent fibroblast stimulation secondary to humoral 
factors may play a role in the severe fibrosis • which 
characterizes PSS. When stimulated with mitogens, 
lymphocytes from patients with PSS produce a factor which 
stimulates human dermal fibroblasts. Lymphocyte mediated 
fibroblast proliferation and collagen production have been 
reported by several groups, but others have shown collagen 
synthesis to be suppressed by mononuclear cell supernatants. 
Jimenez has reported the inhibition of collagen synthesis of 
scleroderma fibroblasts by interferons.94 
A possible role for IL-1 in the pathogenesis of PSS has 
been proposed based on the knowledge that IL-1 can induce 
fibroblast proliferation. Others have suggested that IL-1 
may stimulate fibroblasts to produce collagenase . Both 
increased and decreased IL-1 production by mononuclear cells 
in PSS have been reported. These conflicting reports may be 
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the result of varying laboratory techniques and fibroblast 
culture lines as explained by Korn et al. 
In a recent review, Claman proposes a key role for the 
mast cell in PSS.95 Its role in the pathogenesis of PSS was 
first highlighted when he and colleagues working on rats with 
chronic GVHD noticed the absence of mast cells in the skin of 
these mice. It was later shown that these mast cells had 
degranulated rather than disappeared, rendering them 
undetectable by standard toluidine dye. Later studies on 
skin from patients with PSS showed highly activated mast 
cells. 
The clinical observation that many patients with PSS 
and morphea experience pruritis at involved skin sites 
suggested the presence of histamine release by mast cells. 
Endothelial changes present in scleroderma parallel those 
produced by histamine. The number of mast cells is increased 
preceding the ingrowth of new capillaries in corneal graft 
rejection. It is also known that T-cell derived growth 
factors are capable of activating endothelial cells resulting 
in the changes seen in PSS. Heparin, a substance released 
from mast cells, and other heparin-binding growth factors are 
potent angiogenic stimuli. They also mediate endothelial 
cell and fibroblast proliferation. Other studies have linked 
mast cells and fibroblasts via T-cells. 
In summary, Claman proposes an integrated theory of 
scleroderma in which endothelial cells, mast cells and 
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fibroblasts, all resident cells which regulate connective 
tissue structure and vascular tone (mast cells and 
endothelial cells act on the fibroblast via heparin binding 
growth factors) are activated by invading T-cells, 
macrophages and platelets, all of which secrete a variety of 
factors. Macrophages secrete histamine releasing factors and 
IL-1. T-cells release the mast cell activators IL-3 and IL-4 
and also fibroblast growth factors. Claman concludes that it 
is unlikely that a single factor is responsible for the 
myriad abnormalities seen in PSS, but he emphasizes the need 
to incorporate the mast cell into any comprehensive theory 
highlighting it as a target for future therapeutic 
interventions. 
Treatment. Treatment for patients with PSS remains 
inadequate. At present, therapy for PSS consists of 
supportive measures: calcium channel blockers for the 
control of Raynaud's phenomenon, lanolin based creams for 
skin dryness, physical therapy for contractures, NSAIDS and 
occasional corticosteroids for synovitis and myositis, 
conventional diuretics, digoxin and afterload reducers for 
CHF. Metoclopramide improves esophageal motility for some 
patients. Proper oral hygiene and measures such as small 
meals and esophageal dilatation provide symptomatic relief of 
GI involvement. Aggressive control of hypertension has 
successfully reduced the mortality from scleroderma renal 
crisis with associated malignant hypertension. The 
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angiotensin converting enzyme inhibitors are the mainstay of 
antihypertensive therapy for patients with PSS. 
No single agent slows the disease process effectively. 
D-penicillamine, a drug which interferes with collagen 
cross-linking, may be effective in some patients; however, 
its side effects frequently mandate discontinuation of the 
drug. Colchicine, known to inhibit microtubule function has 
also been advocated, but adequate randomized double-blind 
clinical trials have not been carried out for either of these 
drugs. Corticosteroids are effective in patients with 
myositis or acute pericarditis, but their use in general has 
been disappointing. Results with immunosuppressive drugs 
have been variable. Plasmapheresis has resulted in similarly 
variable results. Controlled trials are urgently needed to 
evaluate the efficacy of the growing number of 
immunosuppressive agents available. Currently a multicenter 
randominized clinical trial of D-penicillamine versus 
photopheresis is underway. 
The considerable experience with photopheresis in the 
treatment of CTCL has spawned numerous clinical trials to 
evaluate the use of this treatment for a variety of diseases 
thought to be T-cell mediated including PSS. Multiple 
immunologic abnormalities are present in PSS. The finding of 
lymphocytes in the skin of patients with PSS is particularly 
notable.® CTCL and PSS are both systemic diseases with 
cutaneous manifestations. T-cell abnormalities are prominent 

41 
in both conditions. Furthermore, peripheral blood cells from 
patients with PSS are reactive with BE2. 
GENE REARRANGEMENTS 
Rapid advances in molecular biology provided the tools 
which enabled scientists to elucidate the mechanisms by which 
antibody diversity is generated.96 Because of the cloning of 
the T-cell receptor genes, investigators have been able to 
demonstrate that these genes rearrange in order to generate 
diversity in a manner analogous to the B cell immunoglobulin 
genes.97 These rearrangements are detectable by Southern 
blotting techniques using cloned DNA fragments as molecular 
probes. 
This technology first became useful in the clinical 
setting as a means for definitively demonstrating the clonal 
nature of neoplasms of B cell lineage. Immunoglobulin gene 
rearrangement analysis is capable of detecting monoclonal B 
cell populations which comprise as little as 1% of the total 
cell population.98 This method thus provides a powerful and 
sensitive means of establishing the diagnosis of B cell 
lymphoma and leukemia in patients with confusing histology or 
when tumor cells lack distinctive antigenic markers. It has 
also been used to show that B cell lymphomas exist which are 
in fact biclonal." 
With the cloning of the genes for the T-cell receptor, 
this approach was extended to the diagnosis of a variety of 
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T-cell lymphoproliferative disorders. The human T-cell 
receptor consists of a disulfide-linked heterodimer composed 
of alpha and beta subunits weighing approximately 40,000 and 
45,000 daltons respectively. Both alpha and beta subunits 
have been cloned.100 In its germline configuration, the gene 
for the beta subunit of the T-cell receptor exists as 
discontinuous gene segments: multiple variable regions (VB) 
and two arrays of diversity (DB1, DB2) , joining (JB1, JB2) 
and constant (CB1, CB2) regions (Figure 1). 
1 
VJ32 DJ3 1 Jfi1(3) ci)2 
-a—□- 
Figure 1. Rearrangement of the T-cell receptor J3 chain genes. 
As the T-cell matures the genes rearrange to generate a 
unique antigenic structure. First a D region gene segment 
rearranges to one of the J region segments. This DJ segment 
then combines with a V gene segment to form a VDJ assembly 
which is associated with either CB1 or CB2.97 Inclusion of 
the D region in the final complex (V(D)JC) is optional. 
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Formation of a complete ft chain mRNA is accomplished by 
splicing. Somatic recombination results in thousands of 
possible combinations. 
Millions of unique T-cell receptor antigen sites may be 
generated by the pairing of the rearranged alpha and beta 
subunits. In addition to somatic recombination, Ig genes 
undergo somatic mutation which contributes to the generation 
of antibody diversity.101 This mechanism has not been 
demonstrated to contribute to the generation of diversity for 
T-cell receptors. 
Molecular probes derived from the T-cell receptor ft 
chain genes can be used to identify distinctive clonal 
populations of T-cells. DNA from a chosen cell population is 
extracted, subjected to digestion with restriction 
endonucleases, size fractionated by agarose gel 
electrophoresis and then transferred to nitrocellulose paper 
according to the method of Southern.102 Hybridization to the 
radioactively labelled probe is followed by autoradiography. 
Each individual T-cell expresses a T-cell receptor with 
unique antigen specificity. Since all diploid cells contain 
two copies of every gene this means that there is expression 
of only one allele of a given antigen receptor gene in any 
cell. If the T-cell receptor loci on both chromosomes have 
undergone rearrangement, only one of these rearranged genes 
is functional, and only the functional rearrangement results 
in mRNA and protein expression. This phenomenon is referred 
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to as allelic exclusion. The specificity and efficiency of 
the immune system depends on this phenomenon. Thus, the fi> 
chain of the T-cell receptor which is expressed on the cell 
surface results from translation of a specific mRNA sequence 
which has been transcribed from a single gene locus which has 
undergone rearrnagement. 
When DNA extracted from peripheral blood containing 
normal polyclonal T-cells is analyzed by Southern blotting, 
distinct bands representing DNA in its germline or 
unrearranged configuration are seen. These germline bands 
reflect DNA from the chromosome which has not undergone 
rearrangement. DNA extracted from monocytes and granulocytes 
also contributes to the intensity of the germline bands. 
If DNA extracted from a pure polyclonal T-cell 
population is analyzed, only the germline bands are seen. 
The unique rearrangements of the polyclonal T-cells result in 
thousands of restriction fragments which are represented as a 
faint smear. The persistence of the germline bands in a 
polyclonal T-cell population reflects those T-cells which 
have undergone a single rearrangement of the T-cell receptor. 
The T-cell receptor genes on the second chromosome remain in 
the germline configuration. 
Rearrangement, which results in the deletion of 
intervening DNA, gives rise to a new restriction fragment by 
altering the 5' restriction enzyme site. This new 
restriction fragment differs in size from the germline bands. 
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If DNA extracted from a cell population containing a 
monoclonal T-cell population is analyzed by this method, a 
new band, distinct from the germline bands is detected. This 
new band consists of DNA fragments which are identical in 
size as they are the result of the clonal expansion of a 
single cell; this results in a population of cells all of 
which carry the same rearrangement. (Figures 2,3) The 
monoclonal population must comprise at least 1% of the total 
population of cells in order for a new distinct band to be 
visible. The intensity of the new band is directly 
proportional to the percentage of cells which comprise the 
monoclonal population. 
In some cases, a T-cell may undergo rearrangement of 
both chromosomes. However, only one of the rearrangements 
results in a functional T-cell receptor which is expressed on 
the cell surface. Nevertheless, the two distinct 
rearrangements are detectable by Southern blot analysis. In 
summary, a single monoclonal population may be reflected by 
the presence of a single new band, or by the presence of two 
new bands depending on whether one or both chromosomes have 
rearranged. 
Numerous studies using this method to detect monoclonal 
populations of T-cells have been carried out on a wide range 
of lymphoproliferative disorders. Minden and Mak have 
summarized the spectrum of conditions which have been 
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genes.103 Several groups have shown that T-cell receptor ft 
chain gene rearrangements occur in patients with T-cell acute 
lymphoblastic leukemia (T-ALL), adult T-cell leukemia (ATL) 
and T-cell chronic lymphocytic leukemia (T-CLL). Unique 
rearrangements have been demonstrated in patients with HTLV-I 
associated adult T-cell lymphoma and nearly all non-Hodgkin's 
lymphomas with T-cell markers. Several groups including 
Berliner et al demonstrated unique T-cell receptor ft chain 
gene rearrangements in patients with T-cell lymphocytosis and 
cytopenia, a rare condition which is perhaps a form of T-cell 
CLL.104 
Gene rearrangement studies are usually helpful in 
defining the lineage of neoplasms lacking lineage-specific 
surface determinants. However, not uncommonly, both Ig and 
T-cell receptor rearrangements are detectible in the same 
cell populations. Patients with non-B non-T ALL may have 
T-cell receptor ft chain rearrangements in addition to Ig 
heavy chain gene rearrangements.105 Approximately 10% of 
patients with chronic B cell malignancies and B cell type 
non-Hodgkin's lymphoma have detectable T-cell receptor ft 
chain gene rearrangements.13 This lineage infidelity106 has 
been interpreted to mean that malignant transformation 
results in genetic deregulation. Alternatively, Greisser et 
al proposed that this dual pattern may reflect a clonal cell 
population that arose from an undifferentiatied hematopoietic 
cell capable of both Ig and T-cell receptor gene 
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rearrangements prior to becoming committed to T or B cell 
lineage.107 A minority of patients with AML have detectable 
rearrangements of the T-cell receptor ft chain genes.108 
As with studies of Ig genes, the availability of 
probes for the T-cell receptor genes has provided a useful 
means of identifying monoclonal populations, establishing the 
lineage of ambiguous tumor populations, and diagnosing 
malignancy. In addition, this method is a sensitive means of 
detecting relapse at an early stage.109 
As previously stated, T-cell receptor gene 
rearrangement studies have proven to be a sensitive and 
practical means of diagnosing CTCL and differentiating it 
from the benign dermatoses.17 They also aid in the diagnosis 
of occult disease. In accordance with other data, Berger et 
al have demonstrated clonal rearrangements in 100% of 
patients with CTCL whom they studied. Four of the 13 
patients with CTCL were also found to have immunoglobulin 
gene rearrangements.110 Ralfkiaer et al employed genotypic 
analysis for improving the diagnosis of extracutaneous 
disease in advanced cases of CTCL.57 
Plaque stage CTCL lesions from multiple sites in the 
same patient were examined in the same study, but the genes 
were found to be in their germline configuration. This 
suggests that T-cell proliferation at this stage may contain 
very small numbers (<1%) of monoclonal cells or may be 
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polyclonal. Most recently, Weiss et al proposed that T-cell 
receptor gene rearrangement studies provide the most 
sensitive means of detecting clonal malignant populations in 
the peripheral blood of patients with CTCL.18 
In light of this background, we chose to use T-cell 
receptor B chain gene rearrangement studies to test the 
hypothesis that BE2 is also a marker of T-cell clonality. 
For these studies, we have used BE2+ and BE2- populations of 
peripheral blood cells from patients with CTCL and unsorted 
peripheral blood cells from patients with PSS whose 
peripheral blood lymphocytes expressed high levels of BE2. 
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MATERIALS AND METHODS 
Patient Samples: Peripheral blood cells were 
obtained from five patients with leukemic phase cutaneous 
T-cell lymphoma and from six patients with progressive 
systemic sclerosis . Blood was collected in heparinized 
tubes. Mononuclear cells were separated by Ficoll-Hypaque 
(Pharmacia Fine Chemicals, Piscataway, NJ) density gradient 
centrifugation. Five to 10 mis of whole blood were placed 
in a 50 ml conical tube and the volume was brought to 35 ml 
with Dulbecco's Ca++ and Mg++ free phosphate-buffered saline 
(PBS) . Ten mis of Ficoll-Hypaque were layered onto the 
bottom of the tube and the tube was then centrifuged at 1500 
rpm for 30 minutes. The mononuclear cells were removed from 
the interface, washed with IX PBS and centrifuged at 1500 
rpm for 10 minutes. The PBS was decanted, leaving a cell 
pellet. 
Cell Marker Analysis: Determination of levels of 
BE2 surface antigen expression was performed by Peter Heald 
and Michael Girardi (Yale University School of Medicine). 
Aliquots of 5x10^ cells were incubated with saturating 
levels of BE2 (gift of Carole Berger, Ph.D.). Following 
primary incubation at 4 deg C for 30 minutes, tubes were 
centrifuged at 300 x g for 30 minutes and washed two times 
with Hanks Buffered Salt Solution (HBBS) with 10% AB serum 
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including .1% sodium azide. Cells then underwent a 20 
minute incubation with goat anti-mouse FITC conjugate 
(Becton-Dickinson, Sunnyvale, CA). Cells were washed again 
and analyzed using a Cytofluorograf Ils/Cell Sorter (Ortho 
Diagnostic Systems, Raritan, NJ). Results were recorded as 
the percentage of positives over background. 
Cell Sorting: Mononuclear cells separated from the 
peripheral blood of patients with CTCL were stained with the 
BE2 surface marker and then sorted using a 
Fluorescence-Activated Cell Sorter (Becton-Dickinson, 
Sunnyvale, CA) into BE2+ and BE2- populations by. Rocco 
Carbone (Yale University School of Medicine). 
DNA Isolation: High molecular weight genomic DNA 
was prepared as follows. Mononuclear cells were incubated 
overnight at 37 deg C in 10 mM Tris/.1 M NaCL/.Ol 
EDTA/.5% sodium dodecyl sulfate with 200 ug/ml 
Proteinase K. The DNA was then extracted once with 
phenol/chloroform/isoamyl alcohol and several times with 
chloroform/isoamyl alcohol. Following extraction, DNA was 
precipitated with ethanol and 10% volume 3M sodium acetate 
and resuspended in 10 mM Tris/1 mM EDTA, pH 7.5 (TE) .111 
The concentration of DNA was determined by optical density 
measurement at A26O using a spectrophotometer. 
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Southern Blot Analysis: Southern blot analysis 
was performed on genomic DNA from each patient including DNA 
isolated from both BE2+ and BE2- mononuclear cell 
populations from patients with CTCL. Genomic DNA (12 
ug/sample) was digested at 37 deg C with the restriction 
enzymes Eco R1 and Hind III (New England Biolabs, Beverly, 
MA). Several samples were also digested with Bam HI (New 
England Biolabs, Beverly, MA). Digested DNA was then size 
fractionated on .9% agarose gel and photographed. The gels 
were denatured in 1.5 M sodium chloride/.5 M sodium 
hydroxide, neutralized in 1 M Tris (pH 8.0)/l.5 M sodium 
chloride, and the DNA was transferred to nitrocellulose 
paper according to the method of Southern.101 Filters were 
hybridized overnight at 42 deg C in 40% formamide/4X SSC (.6 
M sodium chloride/.06 M sodium citrate)/.01 M Tris/lX 
Denhart's solution/ 10% dextran sulfate, containing salmon 
sperm DNA (100 ug/ml) and radioactive probe (1x10^ cpm/ml). 
Following hybridization, filters were washed with 2X SSC (.3 
M sodium chloride/.03 M sodium citrate)/.1% SDS for 20 
minutes at room temperature and for 20 minutes at 55 deg C 
and then in .IX SSC (.15 M sodium chloride/. 0015 M sodium 
citrate) /.1% SDS for 40 minutes at 55 deg C. Filters were 
aut oradiographed for 12-18 hours at -70 deg C with an 
intensifying screen. 
Probe: A Bgl II-Bgl II probe containing the CB2 
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region of the T-cell receptor gene was prepared by enzymatic 
digestion, with the restriction endonucleases Eco R1 and 
Bgl II, of a propagated Escherichia coli plasmid 
containing the T-cell receptor B chain gene (gift from J.G. 
Seidman) . The digested plasmid DNA was then run on a 1% 
agarose gel. A slice of the gel containing the 1 kb 
fragment corresponding to the CB2 region of the T-cell 
receptor gene was cut out and the DNA recovered from the gel 
by electroelution (Elutrap: Schleicher & Schuell, Keene, 
NH). Concentration of the isolated probe was determined by 
analysis on agarose gel. 
The purified probe was radiolabelled with ^2p by nick 
translation according to the method of Rigby et al.110 
Briefly, .2 ug of DNA was dissolved in distilled water and 
incubated at 16 deg C for 35 minutes with the nucleotides 
dATP, dGTP, dTTP at a concentration of .4 mM/L, ^2p 
labelled dCTP (Amersham, Arlington Heights, IL), 10X buffer 
and an enzyme mixture containing DNA polymerase I and DNase 
I in 50% (v/v) glycerol (Nick Translation kit, Boehringer 
Mannheim Biochemicals, Indianapolis, IN). The reaction was 
then stopped with .5 M EDTA/1X STE (10 mM Tris/100 mM NaCl/1 
mM EDTA) and passed over a G50 Sephadex Column (Boehringer 
Mannheim) . One ul was placed on a DE 81 filter and washed 
successively with .5 M Na2HP04/H20/Ethanol. Three mis of 
scintillation fluid was added to a small vial containing the 
DE 81 filter and the number of cpm in one ul of sample was 
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CLINICAL PROFILES: CTCL Patients. Each patient had 
advanced stage CTCL with leukemic involvement. The clinical 
characteristics of these patients are outlined in Table 1. 
Table 1. Clinical Characteristics of Patients with CTCL 
CASE SEX AGE WBC SEZARY CELLS PRIOR TREATMENT RESPONSE 
51 M 55 9.3 10% None + 
68 M 61 15.7 6% Acutane, Tanning 
booth, MTX 
+ 
55 M 42 22.2 19% PUVA, topical 
mustard 
+ 
85 F 72 14 .1 4% Prednisone, UVB, 
topical steroids, N2M 
+ 
70 M 52 11.8 7% topical steroids, 




WBC, white blood count (k/mm3) ; RESPONSE, response to 
photopheresis. 
PSS Patients: Each patient had a positive diagnosis 
of PSS by skin biopsy for less than 2 years and had 30% or 
greater increase in skin involvement in the last six months. 
The patients are all part of a randomized clinical trial of 
D-penicillamine versus photopheresis for treatment of their 
disease. I am the blinded observer for this trial which is 
currently still in progress. Therefore clinical data on 
these patients are not yet available to me. 
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IMMUNOPHENOTYPIC ANALYSIS: Results of BE2 surface 
antigen expression are summarized in Table 2. No data were 
available for PSS patient #4. BE2 expression for PSS patient 
#2 was recorded as divided percentages of lymphocytes and 
monocytes expressing BE2. 
Table 2. BE2 Surface Antigen Expression on Peripheral Blood Cells 
CASE DIAGNOSIS % BE2+ OVER BA 
51 CTCL 57% 
68 CTCL 70% 
85 CTCL 54% 
55 CTCL 34% 
70 CTCL 17% 
1 PSS 25% 
2 PSS 10% lymphs 
3 PSS 19% 
4 PSS ND 
5 PSS 24% 
6 PSS 36% 
72% monos 
ND, not determined. 
CELL SORTING: CTCL cases 68, 85 and 55 were sorted by 
FACS. In case 68 the BE2+ population was the high 35% of 
the sort. The BE2- population was the low 10% of the sort. 
In case 85 the BE2+ population was the high 30% of the sort, 
and the BE2- population the low 30% of the sort. In case 55 
the BE2+ population was the high 15% of the sort, and the 
BE2- population was the low 20% of the sort. Cases 51 and 
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70 were sorted using magnetic beads into BE2+ and BE2- 
populations . 
DETECTION OF T-CELL RECEPTOR 
REARRANGEMENT: The germline organization of 
locus is diagrammed in Figure 4. 
B CHAIN 
the !i chain 
C/3 PROBE ■ 
i—i ' • • 
5' 
—//-fl- «— 
J13(1-7) CJ32 3' 
-//- 
—// ii iii i iii / f—r 
R1 H H R1 H R1 R1 H R1 H 
Figure 4. Germline organization of the T-cell receptor 13 chain genes. The locations 
ofthefb?R1 and Mnd \\\ re3triction-endonuclea3e sites are indicated. Southern blot 
analysis was performed using a 1 kb Bgl II - Bgl 11 probe from C132 which recognizes both 
constant regions. 
genes. The CI5 genes are present on two Eco R1 fragments of 
10.8 kb and 3.7 kb (Figure 2). The 10.8 kb fragment is the 
result of hybridization to CI31. This fragment contains the 
Jfll gene region, allowing rearrangement into this region to 
be detected. The 3.7 kb fragment results from hybridization 
to CB2 . This fragment does not contain a J region thereby 
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making rearrangement in this region undetectable by this 
digest. The Cft genes are present on three Hind III fragments 
of 7.5 kb, 6.5 kb and 3.4 kb (Figure 3) . The 7.5 kb band 
results from hybridization to a Cft2 fragment containing the 
Jft2 region. Thus rearrangements involving Cft2 will be 
detected due to an alteration in the 5' restriction site. 
The 6.5 kb and 3.4 kb fragments result from hybridization to 
Cft2 and Cftl, respectively. These fragments lack J regions, 
and therefore do not allow detection of rearrangements. Thus 
digestion with Eco R1 allows detection of T-cell receptor ft 
chain rearrangements involving Cftl, and digests using Hind 
III allow detection of Cft2 gene rearrangements. 
Unique T-cell receptor ft chain rearrangements were 
detected in unsorted samples from all CTCL patients studied. 
Furthermore, the rearrangements detected were present in both 
BE2+ and BE2- populations. Four of these cases are 
illustrated in Figure 5. Case 51 showed rearrangement of Cftl 
and Cft2. All other cases revealed only rearrangement of Cft2. 
The rearranged band in Case 51, indicated by an arrow, 
occurs at approximately 7 kb. The germline bands are present 
at 10.8 kb and 3.7 kb. In the unsorted population, an extra 
band is present at 9 kb. This band suggests rearrangement of 
Cftl, but has been noted in DNA extracted from the peripheral 
blood of normal controls.103 This artifact has also been 
detected in Eco R1 digests of DNA extracted from 
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Figure 5. Southern blot analysis of DNAs from patients 
with CTCL. Eco Rl and Hind III digested DNAs were 
size-fractionated on .9% agarose gels and blotted on 
nitrocellulose as described in the Materials and Methods. 
Filters were hybridized to the CB2 probe. Autoradiograms 
revealed extra bands indicative of somatic rearrangements in 
all 4 cases. Rearranged bands are indicated by arrows. In 
all cases, identical banding patterns were observed in 
unsorted (UNS), BE2+ and BE2- cell populations. Case 51 
revealed rearrangement of Cftl. An aberrant band representing 
an artifact is present in the unsorted population. The extra 
bands in cases 68, 55 and 85 indicate rearrangement of CJ32 . 
The extra band seen in all populations in case 68 is most 




Figure 6. Autoradiogram demonstrating the presence of 
an aberrant band in Eco R1 digests of granulocytes and 
lymphocytes from normal controls. This artifact is probably 
of no biologic significance. 
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band in granulocytes and lymphocytes from 2 normal 
individuals. This aberrant band is not visible in the BE2+ 
and BE2- sorted cell populations from Case 51. This finding 
most likely reflects the low DNA yield obtained from these 
sorted specimens. Even the germline bands are less intense 
in these populations reflecting the fact that fewer 
micrograms of DNA were available for Southern blotting. The 
decrease in the intensity of the 10.8 kb band relative to the 
other bands is explained by the presence of the monoclonal 
population which has rearranged to the CI51 locus on one 
chromosome. 
In addition, digestion with the restriction enzyme Hind 
III revealed the presence of an extra band representing a 
second rearrangement involving C152 . Rearrangement to CB2 
necessitates the deletion of the Cfil locus; this results in 
a further decrease in the intensity of the 10.8 kb band which 
reflects hybridization to Cfil. Thus the monoclonal T-cell 
population in case 51 has rearranged on both chromosomes: to 
Cfil on one chromosome and to Cfi>2 on the other. This results 
in the presence of an extra band in both Eco R1 and Hind III 
digests. The continued presence of the 10.8 kb germline band 
indicates that normal mononuclear cells remain. The 
monoclonal population does not comprise 100% of the total 
T-cell population. The germline band is present in both BE2+ 
and BE2- populations demonstrating unequivocally the presence 
of BE2+ normal cells in a patient with CTCL. 
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In Case 68 a unique rearrangement involving CB2 results 
in a distinct band indicated by an arrow in Figure 5. The 
germline bands at 7.5 kb and 3.4 kb are decreased in 
intensity. The 7.5 kb fragment, which contains the J region 
of the CB2 locus, is appropriately reduced in intensity as 
this locus is utilized in the new rearrangement. A decrease 
in the 3.4 kb band which results from hybridization to Cftl, 
also reflects the rearrangement to CB2 which deletes CB1. An 
extra band is seen below the 6.5 kb band. This band was 
present in all lanes probed including lanes containing DNA 
extracted from patients without a detectable clonal 
population. In addition, the extra band is relative ’to DNA 
concentration. It is most likely the result of contaminating 
genomic sequences in the probe. Additional DNA was not 
available to repeat the blot. The relative faintness of the 
bands in the BE2- population is secondary to the low DNA 
yield obtained from these cells. Nevertheless, it is clear 
that no difference exists in the banding patterns seen in the 
three cell populations. 
Cases 55 and 85 were run in parallel. The three 
germline bands are shown clearly in Case 55. A new band 
representing a unique rearrangement of CB2 is seen just above 
the 6.5 kb germline band. This band is decreased in 
intensity when compared to the 6.5 kb and 3.4 kb germline 
bands. The 7.5 kb band which contains the J region of CB2 is 
appropriately decreased in intensity in accordance with the 
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presence of a clonal population which rearranges to Cft2 . 
Case 85 is particularly interesting. The 6.5 kb 
germline band is visible. This band, which results from 
hybridization to a Cft2 containing fragment which hybridizes 
to the 3 ' end of the probe is unaffected by rearrangement 
into either Cftl or Cft2 , Because the 5 ' end of the 
hybridizing fragment does not include the J region, it is 
invariant. However, the other two germline bands have been 
deleted. Two new bands, indicated by arrows, are present in 
both BE2 + and BE2- populations. These bands reflect a 
monoclonal T-cell expansion. These bands correspond to two 
rearrangements of Cft2, reflecting a population in which the 
T-cell ft chain locus has rearranged on both chromosomes. 
The absence of the two germline bands indicates that 100% of 
the cells are tumor cells. No normal cells containing 
germline DNA remain. 
The 3.4 kb fragment, which reflects hybridization to 
Cfll, is not visible because the two rearrangements to the Cft2 
locus result in deletion of Cfil on both chromosomes. The 7.5 
kb fragment containing the J region of Cft2 has also 
completely disappeared as all of the cells have undergone 
rearrangement which necessitates an alteration in the 
restriction site pattern. Both BE2+ and BE2- populations 
demonstrate identical banding patterns. Furthermore, the 
observation that 100% of the cells belong to a single clonal 
expansion provides definitive evidence that both BE2+ and 
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BE2- tumor cells exist. 
Rearrangements involving the T-cell receptor 13 chain 
were not detected by Southern blotting in any of the DNA 
samples extracted from patients with PSS. DNA was in the 
germline configuration in all samples. Six of these cases 
are illustrated in Figure 7. The above mentioned Eco R1 
artifact was observed in Cases 3 and 5. A decrease in the 
intensity of the 10.8 kb fragment is particularly striking in 
cases 2 and 4. This finding indicates the presence of a 
significant polyclonal T-cell population in these peripheral 
blood samples. 
As explained above, this 10.8 kb fragment results from 
hybridization to a C131 gene segment which contains a J 
region. This fragment is altered in size by rearrangements 
using C131. The CI31 locus is deleted by rearrangements to 
CJ32 . Therefore, a decrease in the intensity of the 10.8 kb 
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Figure 7. Autoradiograms of Eco R1 and Hind III digests 
of DNAs from 6 patients with PSS. In each case, DNA is 
present in its germline configuration. The Eco R1 artifact 
is visible in cases 3 and 5. The decreased intensity of the 
10.8 kb band relative to the 3.7 kb band in cases 2 and 4 





The detection of clonal T-cell populations by DNA 
analysis has contributed greatly to our understanding of 
many lymphoproliferative disorders. This technology has also 
improved our ability to diagnose clonal disorders and to 
detect disease recurrence. In this study, we have applied 
gene rearrangement studies, using the 15 chain of the T-cell 
receptor, to investigate the origins of cells bearing the BE2 
surface marker. We have shown that surface expression of BE2 
does not predict a clonal T-cell expansion in either CTCL or 
PSS. 
Peripheral blood cells from patients with CTCL were 
sorted into BE2- and BE2+ populations by FACS. As previously 
stated. Southern blot analysis of the T-cell receptor 15 chain 
genes is capable of detecting a clonal population which 
comprises as little as 1% of the total population of 
cells.14'16 Although the cells were meticulously sorted, the 
possibility of some overlap between the two populations of 
cells exists. However, identical banding patterns were 
observed in both populations. There was no detectable 
difference in the percentage of monoclonals in the BE2+ and 
the BE2- populations. 
The finding that 100% of the cells containing DNA in 
case 85 are tumor cells renders our conclusion that both BE2 + 
and BE2- clonal tumor cells exist in CTCL unambiguous. 
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Since the cells are not 100% BE2 + , BE2 does not identify the 
monoclonal T-cell population in CTCL. In addition, case 51 
definitively demonstrates the presence of BE2+ normal 
mononuclear cells. Consequently, we have detected both BE2+ 
normal cells and BE2- tumor cells in the peripheral blood of 
patients with CTCL. Additional evidence that BE2 does not 
correlate with T-cell clonality is provided by our data on 
PSS patients. 
The finding of an aberrant band in Eco R1 digests from 
the unsorted cell population from Case 51 and from normal 
individuals illustrated in Figure 6 deserves mention. This 
artifact, which as noted by other investigators do.es not 
correspond to a clonal T-cell expansion, 103,12 -j_s probably of 
no biological significance. However, this technical 
aberrancy necessitates that rearrangements of Cfil be 
interpreted cautiously. 
There are several important clinical conclusions which 
may be drawn from our study. To begin with, BE2 expression 
does not correlate with tumor burden in CTCL. While BE2 may 
be a cell surface marker expressed on lymphocytes in the 
peripheral blood of approximately 75% of patients with CTCL, 
both BE2 + and BE2- tumor cells and BE2+ normal mononuclear 
cells are present in the peripheral blood of patients with 
CTCL. This has several implications. 
First, a tumor specific marker can be tagged with a 
number of toxic compounds which could selectively eliminate a 
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tumor population. It is clear from these studies that BE2 
will not be useful as a new weapon in our therapeutic 
armamentarium. 
Second, if BE2 were a tumor specific marker, it could 
potentially be a useful diagnostic tool in CTCL, especially 
since surface marker analysis is now routinely performed at 
many medical centers. In particular, it would be useful for 
detecting early peripheral blood involvement. Surface marker 
analysis is both more rapid and less labor intensive than 
gene rearrangement studies. Our results militate against the 
diagnostic usefulness of BE2 in CTCL. 
The clinical case histories of the patients studied in 
this thesis underscore the frequently noted diagnostic 
challenge CTCL poses in its early stages. In case 51, the 
patient was initially thought to have a fungal skin 
infection. Over a year elapsed during which the patient in 
case 68 had prominent cutaneous manifestations until the 
diagnosis of CTCL was made. The patient in case 85 was 
treated with prednisone for an elusive "inflammation" before 
her diagnosis was made. Similarly, in case 70 the patient 
was treated with moisturizers and topical steroids for a 
waxing and waning eruption for two years prior to his 
diagnosis. 
The usefulness of gene rearrangement studies in the 
detection of leukemic progression in CTCL has not been 
extended to the diagnosis of plaque or early stage CTCL. 
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Early diagnosis has well-documented therapeutic importance. 
Ralfkiaer et al analyzed DNA extracted from multiple skin 
biopsy specimens from 8 patients with plaques clinically 
suspicious, but histologically nondiagnostic, for early CTCL 
and 4 patients with plaque or stage II mycosis fungoides.57 
In each case, germline configuration of the T-cell receptor fl 
chain gene was demonstrated. 
In contrast, DNA from skin biopsy samples from patients 
with advanced CTCL revealed T-cell receptor ft chain 
rearrangement. The author concludes that this method is not 
a useful diagnostic test for early CTCL, perhaps because the 
disease is polyclonal at this stage or perhaps because a 
monoclonal expansion if present is below the level of 
detection of this method. It would be interesting to know if 
those patients in whom rearrangements were not detected went 
on to develop advanced CTCL because only 4 of 12 had 
histologic evidence of CTCL. Additional studies to evaluate 
the usefulness of this technique in early CTCL should be 
done. 
In a paper proposing BE2 as an activation marker, Heald 
and Berger stated that future studies should aim to identify 
biologic differences between BE2+ and BE2- cell populations.5 
Our findings raise the possibility that CTCL is a dynamic 
disease in which tumor cells may convert from a BE2- to a 
BE2+ state or vice versa. The in vitro induction of BE2 
expression on BE2- cells from CTCL patients has been shown. 
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We have further demonstrated the simultaneous in vivo 
existence of BE2+ and BE2- tumor cells and BE2+ normal cells. 
This data concurs with the idea that BE2 is an activation 
marker. 
If BE2 is an activation marker whose expression can be 
induced on normal lymphocytes in vitro, and if it does not 
define the monoclonal population in CTCL, then what is its 
role in the response to photopheresis? In the initial trial 
of photopheresis, decreased BE2 expression was correlated 
with clinical response in a subgroup of patients who 
responded to the treatment. Our study indicates that 
although alterations in BE2 expression may be an empiric 
marker of clinical response to photopheresis, they probably 
do not correlate directly with cytotoxic activity against the 
malignant clone. This conclusion is further supported by the 
observation that in our group of 5 patients with advanced 
CTCL, BE2 expression remained relatively constant in 2 
patients, decreased in one and became elevated in another 
patient who also showed a dramatic increase in his white 
count. A fifth patient who was markedly positive at the time 
of our study, had been previously BE2- and converted to BE2 
positivity after beginning photopheresis treatment. Despite 
this heterogeneity of response of BE2 expression, all of 
these patients showed response to photopheresis. 
It has been proposed that scleroderma may be a T-cell 
mediated disease.8 However, there are no reports in the 
- . 
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literature of studies attempting to identify a clonal T-cell 
expansion in the peripheral blood of patients with PSS. We 
hypothesized that BE2 expression may identify a monoclonal 
T-cell expansion in PSS. To test this hypothesis, we 
analyzed DNA extracted from mononuclear cell preparations 
from patients with PSS for evidence of a monoclonal T-cell 
population. Germline configurations of the B chain genes 
were found in each case, confirming that BE2 expression does 
not correspond to a monoclonal T-cell expansion in the 
peripheral blood of patients with PSS. Furthermore, our 
studies confirm that if a clonal T-cell expansion is present 
in the peripheral blood of patients with PSS it comprises 
less than 1% of the total peripheral blood cell population. 
It is conceivable that a pathogenic T-cell clone may reside 
in the skin or other affected organs of patients with PSS. 
Cellular epidermal infiltrates seen in patients with PSS are 
comprised primarily of T-cells.8 Gene rearrangement studies 
on DNA extracted from skin biopsy specimens could be done to 
determine if these T-cells are the result of a monoclonal 
expansion. 
The lack of an identifiable monoclonal T-cell expansion 
in the peripheral blood of patients with PSS has other 
implications. First, if photopheresis induces a clonotypic 
response, then one would expect its efficacy in PSS to be 
limited. The results of this trial are not complete; 
however, if photopheresis does prove to be effective in PSS, 
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then this theory becomes less plausible as a therapeutic 
mechanism in PSS. Instead, a more general mechanism of 
action would be likely. 
The sustained clinical response seen in CTCL patients 
successfully treated with photopheresis suggests some sort of 
immunologic suppression of the malignant clone. Surely, the 
responses achieved with photopheresis are out of proportion 
to simple cytotoxic destruction of malignant cells in the 
peripheral blood. Results from studies employing animal 
models have suggested that photopheresis may induce specific 
suppression of immunoactive T-cells.82 Generalized 
suppression of activated polyclonal T-cells which would be 
capable of B cell stimulation could conceivably have an 
effect on the progression of autoimmune disease. This 
hypothesis could be investigated by comparing the interaction 
of serum and tumor cells extracted from a CTCL patient before 
and after photopheresis. This might indicate if the serum 
contains factors which are cytotoxic to the tumor cells. A 
cellular mechanism could be investigated by similar studies 
aimed at looking at the interaction of patients' T and B 
cells pre- and post therapy. 
The presence of BE2 in CTCL and PSS, both systemic 
diseases with cutaneous manifestations, is intriguing. If 
BE2 is an activation marker, it would be useful to know if it 
is expressed in other diseases with cutaneous manifestations 
such as chronically transfused patients, ARC patients who 

present with eczema, or patients with drug rashes secondary 
to phenytoin or methyldopa. In addition, it would be 
important to determine if it is expressed on the peripheral 
blood cells of patients with other purportedly T-cell 
mediated diseases for which trials of photopheresis are 
underway, particularly if BE2 expression may help predict 
which patients will respond to photopheresis. 
In vivo activated T-cells have been demonstrated in the 
peripheral blood and CSF of patients with multiple 
sclerosis112, and very late activation antigens have been 
detected on synovial fluid lymphocytes from patients with 
rheumatoid arthritis.113 Additional investigative studies 
should help to define better the role of activated T-cells in 
autoimmune disease. 
Southern blot analysis of the T-cell receptor genes is 
now being used to help understand the pathogenesis of a 
variety of autoimmune diseases. Distinct rearrangements of 
the T-cell receptor B chain have been demonstrated in 
cultured T-cells from RA synovial infiltrates.114 T-cells 
extracted from the peripheral blood of RA patients showed no 
evidence of rearrangement. Synovial fluid mononuclear cells 
also showed no evidence of B chain rearrangement.115 Tesch 
et al recently applied this technique to the analysis of the 
thymus in myasthenia gravis.116 Gene rearrangement studies 
contributed greatly to our understanding of 
lymphoproliferative disorders. Their application to the 
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study of autoimmune disease may contribute to our 
understanding of its pathogenesis. 
Our study may be viewed as an important step in further 
characterizing the BE2 surface antigen and further 
understanding its significance and usefulness with respect to 
photopheresis. The technology needed to clone BE2 is now 
available. The cloning of BE2 would allow investigators to 
compare the antigen to known sequences and to design 
experiments to elucidate its function. In the meantime, 
additional clinical studies such as those proposed above 
could establish the marker as an important diagnostic tool. 
Finally, understanding BE2 may help to elucidate the 
mechanism of photopheresis - a powerful therapeutic tool 
which may become even more useful once its mechanism of 
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